Background: Histamine is associated with carcinogenesis through activation of its 4 membrane-specific receptors. We evaluated the anti-tumour effect of clobenpropit, which is the specific H 3 antagonist and H 4 agonist, with gemcitabine combination in pancreatic cancer cell line. Methods: Three kinds of human pancreatic cancer cell lines (Panc-1, MiaPaCa-2, and AsPC-1) were used in this study. Expression of H 3 and H 4 receptor in pancreatic cancer cell was identified with Western blotting. Effects of clobenpropit on cell proliferation, migration and apoptosis were evaluated. Alteration of epithelial and mesenchymal markers after administration of clobenpropit was analyzed. In vivo study with Panc-1 xenograft mouse model was also performed. Results: H 4 receptors were present as 2 subunits in human pancreatic cancer cells, while there was no expression of H 3 receptor. Clobenpropit inhibited cell migration and increased apoptosis of pancreatic cancer cells in combination with gemcitabine. Clobenpropit up-regulated E-cadherin, whereas down-regulated vimentin and matrix metalloproteinase 9 in real-time PCR. Also, clobenpropit inhibited tumour growth and enhanced apoptosis in combination with gemcitabine by up-regulation of E-cadherin and down-regulation of Zeb1 in Panc-1 xenograft mouse. Conclusion: Clobenpropit enhanced anti-tumour effect of gemcitabine in pancreatic cancer cells through inhibition of epithelialmesenchymal transition process.
INTRODUCTION
Pancreatic cancer is a very aggressive human cancer and has dismal prognosis with only 6% of patients survive 5 years after diagnosis (Siegel et al, 2012) . In spite of the progresses of treatments, the attempts of survival prolongation, especially in the advanced stage, have failed and resulted in no significant improvement (Hidalgo, 2010) . Surgical resection is the only potentially curative treatment in pancreatic cancer, but only 15% of patients could be candidate for resection (Conlon et al, 1996; Mancuso et al, 2006) . Some chemotherapeutic agents are used in pancreatic cancer, and gemcitabine became the standard chemotherapeutic agent in pancreatic cancer since the randomized trial in 1997 (Burris et al, 1997) . Gemcitabine is a nucleoside pyrimidine analogue which exerts its cytotoxic actions primarily by the incorporation of gemcitabine triphosphate into DNA, leading to masked chain termination (Huang et al, 1991) . However, pancreatic cancer is highly resistant to chemotherapy including gemcitabine (Ying et al, 2012) , and the disappointing circumstance of pancreatic cancer is mainly due to late diagnosis at which chemoresistance in patients is a critical issue (Hung et al, 2012) . Resistance to gemcitabine has been increasing and the effectiveness of gemcitabine has been reduced to less than 20% (Bafna et al, 2009 ). Hence, new therapeutic targets and chemotherapeutic agents of pancreatic cancer are desperately required.
High concentration of histamine has been shown in melano-ma (Hegyesi et al, 2001 ), small cell lung carcinoma (Graff et al, 2002) , breast carcinoma (Garcia-Caballero et al, 1994) and colorectal carcinoma (Garcia-Caballero et al, 1988) . Histamine participates in tumour proliferation or apoptosis through activation of its four membrane-specific receptors, H1, H2, H3 and H4 (Cianchi et al, 2008) . As in other human cancers, expressions of histidine decarboxylase and histamine contents have been reported in pancreatic cancer Tanimoto et al, 2004) . Histamine inhibits the cell proliferation through H1 and H2 receptor, which is associated with a partial differentiation in pancreatic cancer . Through H2 receptor, histamine induces G0/G1 phase arrest and modulation of mitogen activated protein kinase (MAPK) and Bcl-2 family proteins Furthermore, the previous study suggests that H3 and H4 receptors are involved in pancreatic cancer cell growth, with proliferation increased through H3 receptor and diminished via H4 receptor . However, the mechanism of anti-cancer effect through histamine receptor still remains unclear.
Clobenpropit, which is a specific H3 antagonist and H4 agonist, inhibits the spread of mammary adenocarcinoma by decreasing invasion potential . The recent study suggested that the modulation of H4 receptor by clobenpropit disrupts epithelial-mesenchymal transition (EMT) processes, extracellular matrix (ECM) breakdown, and invasion potential and decreases tumour growth in cholangiocarcinoma (Meng et al, 2011) . Similarly, EMT plays a crucial role in tumour progression and metastasis of pancreatic cancer (Nakajima et al, 2004) . Furthermore, EMT regulators including Zeb1 are known to induce chemoresistance of human pancreatic cancer cells (Arumugam et al, 2009 ). Thus, therapeutic agents targeting EMT process could restore the chemoresistance of pancreatic cancer. Therefore, we aimed to investigate the anticancer efficacy of clobenpropit with gemcitabine combination in human pancreatic cancer cells. Additionally, we evaluated the alteration of EMT markers after administration of clobenpropit with in vitro and in vivo studies. and/or gemcitabine (5 μM) were treated, H4 receptor expression was also showed but not significantly changed in all cell lines (Fig. 1B) .
MATERIALS AND METHODS

Clobenpropit inhibited cell migration by inhibition of EMT
process. The inhibition of cell migration was assessed by wound healing assay. Clobenpropit inhibited the migration of pancreatic cancer cells in wound healing assay (Fig. 2) . Wound healing ranges were more decreased depending on the higher clobenpropit concentration. In addition, the migration rate was also inhibited after treatment of gemcitabine and clobenpropit combination compared with control and gemcitabine or clobenpropit alone ( Supplementary Fig. S1 ).
To investigate the mechanism of clobenpropit to the cell migration, real-time PCR about epithelial and mesenchymal markers was performed. E-cadherin was about 4-fold increased after treatment of clobenpropit in Panc-1. MMP-9 was reduced in MiaPaCa-2, and vimentin and MMP-9 were reduced to about half after treatment of clobenpropit in AsPC-1 ( Supplementary Fig.   S2 ). Therefore, clobenpropit down-regulated epithelial marker, while up-regulated mesenchymal markers and it means that clobenpropit might disrupt EMT process of pancreatic cancer cells.
Clobenpropit enhanced gemcitabine-induced apoptosis. Clobenpropit alone did not affect the proliferation of pancreatic cancer cells ( Supplementary Fig. S3 ). However, the exposure to gemcitabine (5 μM) and/or clobenpropit (50 μM) induced apoptosis of pancreatic cancer cells. Gemcitabine and clobenpropit combination therapy significantly increased apoptosis of Panc-1, MiaPCa-2 and AsPC-1 compared with control (Fig. 3) . However, gemcitabine alone did not increase apoptosis of pancreatic cancer cells significantly compared with control.
Xenograft mouse model. In the xenograft mouse model of Panc-1, the body weight of mice was checked every week ( compared with other treatment groups ( Fig. 4B and C ).
E-cadherin was up-regulated after clobenpropit administration in real-time PCR (Fig. 5A) . Also, immunohistochemical staining showed up-regulation of E-cadherin in clobenpropit alone and combination group (Fig. 5B) . To quantify apoptosis of tumours, TUNEL staining was performed. The percentage of TUNELstained cells was more increased in gemcitabine and clobenpro- pit combination group compared with other groups (Fig. 5C ).
The expression of E-cadherin was also increased in clobenpropit alone and combination group by Western blotting, whereas Zeb1 expression, the repressor of E-cadherin, was decreased in combination group (Fig. 5D ).
DISCUSSION
The role of histamine and its receptors in carcinogenesis is complex and somehow confusing. We evaluated the effect of specific histamine receptor and its agonist against human pan- . Real-time PCR shows that E-cadherin was upregulated (A), whereas MMP-9 and vimentin were downregulated (B, C) in pancreatic cancer cells after treatment with different concentration of clobenpropit.
